Physician profile
Pai H Chen
NPI 1063405892
$6,638.09
in general payments reported to CMS, 2019-2025
25 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $165 · 2023: $1,733 · 2024: $2,348 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,815 · Travel and Lodging: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,814.70 |
| Travel and Lodging | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $875.54 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $558.21 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $504.12 | 2023-2025 | Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $467.62 | 2023-2024 | Austedo Xr, Austedo |
| Phathom Pharmaceuticals, INC. | $447.32 | 2024-2025 | Voquezna |
| Eisai INC. | $394.38 | 2024-2025 | |
| Pfizer INC. | $373.32 | 2023-2025 | |
| Amarin Pharma, INC. | $306.99 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $249.97 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $249.97 | 2023-2025 | Rexulti |
| Abbvie INC. | $249.96 | 2023 | Linzess |
| Janssen Pharmaceuticals, INC | $237.39 | 2019 | |
| Cmp Pharma, INC. | $237.32 | 2023 | Norliqva |
| Exact Sciences Corporation | $157.31 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $146.62 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $140.00 | 2025 | |
| Lilly USA, LLC | $137.05 | 2024 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $124.99 | 2024 | Nexlizet, Nexletol |
| Ars Pharmaceuticals Operations, INC. | $124.99 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2024 | Jardiance |
| Axsome Therapeutics, INC. | $124.98 | 2025 | Symbravo |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $121.83 | 2025 | Zoryve |
| Gilead Sciences, INC. | $36.39 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pai Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.